The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

The class of GLP-1 agonist medications act by lowering the appetite with applications way beyond diabetes. These medicines ...

Novo Nordisk’s blockbuster diabetes drug, Ozempic, was officially launched in India on December 12. Unlike in the US and ...

Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 (approx ₹ 2,200) per week, as it seeks ...

Danish pharmaceutical company Novo Nordisk today launched its blockbuster type 2 diabetes treatment injection Ozempic in ...

There’s trouble brewing beneath the GLP-1 buzz. As Americans embrace blockbuster weight-loss drugs like Ozempic and Wegovy in ...

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli ...

Dec 12 (Reuters) - The European Medicines ‌Agency's ​committee on Friday ‌recommended extending the use of Eli Lilly's ...

Today, the European Medicines Agency’s Committee for Medicinal Products for Human Use, CHMP, issued a positive opinion for a ...

Novo Nordisk said on Friday the European ‍Medicines Agency's committee has issued a positive opinion for a 7.2 mg dose of ...

Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming ...

Novo Nordisk launched Ozempic in India on Friday—and the weight-loss drug will sell at a massive discount there, compared ...